Eisai Presents Results of Lecanemab in P-IIb Study 201 Study for the Treatment of Alzheimer's Disease at CTAD 2021
- The P-IIb Study 201 trial evaluates the efficacy of lecanemab vs PBO in 856 patients with MCI due to AD and mild AD
- The results showed robust clearance of brain amyloid and demonstrated clinical decline across multiple clinical and biomarker EPs. Additionally, the therapy showed consistent treatment effect across multiple statistical methods @18mos. for ADCOMS, CDR-SB, and ADAS-Cog14.
- Lecanemab is currently being evaluated in the P-III AHEAD 3-45 study in patients with preclinical AD, based on the P-II Study 201 study. A pre-specified analysis of Study 201 study demonstrated reduction of brain Aß accumulation & slowing of disease progression in early AD
Ref: Biogen | Image: Pharmaletter
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at email@example.com